Get the Stockscreener App
3.88
1.02%
-0.04
Galmed Pharmaceuticals Ltd stock is traded at $3.88, with a volume of 4,100.
It is down -1.02% in the last 24 hours and down -15.71% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
See More
Previous Close:
$3.92
Open:
$4.0749
24h Volume:
4,100
Relative Volume:
0.04
Market Cap:
$4.04M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-1.6647
EPS:
-2.3308
Net Cash Flow:
$-6.32M
1W Performance:
-6.84%
1M Performance:
-15.71%
6M Performance:
-17.46%
1Y Performance:
-62.11%
1-Day Range:
$3.88
$4.23
1-Week Range:
$3.8176
$4.23
52-Week Range:
$3.2888
$13.20
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
3.88 | 4.75M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Pharmaceuticals Ltd.: Financial Data Forecasts Estimates and Expectations | GLMD | IL0011313900 - marketscreener.com
Galmed completes colon tissue assessment study - grafa.com
Galmed completes feasibility study for colon tissue assessment tech By Investing.com - Investing.com Nigeria
Galmed’s Colospan Unit Reports Successful First-in-Human Study for New Colorectal Surgery Platform - TipRanks
Colospan completes successful study on new colo... - Pluang
Galmed completes feasibility study for colon tissue assessment tech - Investing.com
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PR Newswire
Galmed Reports Aramchol–Xtandi Combo Boosts Prostate Cancer Cell Death in Pre-Clinical Study - TipRanks
Galmed reports pre-clinical data on Aramchol-enzalutamide combo - Investing.com
Galmed reports pre-clinical data on Aramchol-enzalutamide combo By Investing.com - Investing.com UK
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - Yahoo Finance Singapore
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026 - TipRanks
Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026 - Stock Titan
Galmed Pharmaceuticals (GLMD) Slips 6.1% to $0.56 as Selling Pressure IntensifiesIchimoku Kumo Twist - Vinanet
Galmed Pharmaceuticals (GLMD) Holds at $0.60 as Micro-Cap Biotech Trades Between Key LevelsHigh Yield Stocks - Vinanet
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals (GLMD) Rises 5.4% to $0.62, Approaching Key ResistanceOpening Range Breakout - vinanet.vn
GLMD Q1 2026 Earnings: Surprise Profit Beats Estimates as Shares Gain 5.4%Earnings Deceleration Risk - Vinanet
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2026 Earnings: Surprise Profit Driven by Expense Management and Non-Operating GainsEarnings Power Value - dars.gov.et
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PR Newswire
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.602|Chg%:-0.004 - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.523|Chg%:-0.008 - TradingKey
Galmed Pharmaceuticals (GLMD) Slides 5.4%: Testing Key Support After Bearish MoveSymmetrical Triangle - vinanet.vn
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - The Globe and Mail
Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
GLMD Q1 2026 Earnings: Stellar EPS Surprise Despite Revenue Absence and Stock DeclineMargin Compression Risk - vinanet.vn
Galmed unveils heart-targeted Aramchol in cardiac fibrosis push - Indian Pharma Post
Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com South Africa
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
Galmed develops heart-targeted formulation of Aramchol drug - Investing.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PR Newswire
Galmed Pharmaceuticals (GLMD) Slips 2.16% as Shares Test Key Support Near $0.47Pairs Trade - vinanet.vn
Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near SupportPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals (GLMD) Holds Steady at $0.57: Consolidation Phase with Key Levels in FocusSkew Index - dars.gov.et
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040 - TradingKey
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2025 Earnings: EPS Miss Extends Losses as Pre‑Revenue Biotech Faces Pipeline UncertaintyAnalyst Coverage Count - dars.gov.et
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):